NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim

Trial Profile

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Lipegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Acronyms NADIR
  • Most Recent Events

    • 11 Oct 2016 Planned number of patients changed to 2500.
    • 11 Oct 2016 Interim results in 2422 patients (data cut-off date march 2016) presented at the 41st European Society for Medical Oncology Congress
    • 23 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top